Kym N. Lowes

University of Melbourne — Australia

Medicine · Health Sciences

22h-index3.8kcitations63works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Malaria Research and Control(17), Cell death mechanisms and regulation(11), Computational Drug Discovery Methods(10), Muscle Physiology and Disorders(6), Research on Leishmaniasis Studies(6)

Publications63 total

MK-7602: a potent multi-stage dual-targeting antimalarial
EBioMedicine·2025· 1 citedOpen Access
Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity
PLoS Pathogens·2025· 2 citedOpen Access
Global analysis of cancer cell responses to USP9X inhibition
2025· 1 citedOpen Access
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID
Nature Communications·2025· 22 citedOpen Access
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules
Science Advances·2025· 6 citedOpen Access
A novel PLpro inhibitor scaffold that protects mice from Long-COVID
2024· 1 citedOpen Access
Differential regulation of BAX and BAK apoptotic activity revealed by a novel small molecule
2024
Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape
Nature Communications·2024· 15 citedOpen Access
Mutational Profiling of SARS-CoV-2 PLpro in human cells reveals requirements for function, structure, and drug escape
2024Open Access
Abstract C043: Discovery of new drug combinations for metastatic colorectal cancer
Molecular Cancer Therapeutics·2023
The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
Biochemical Journal·2023· 12 citedOpen Access
CCDC 2224865: Experimental Crystal Structure Determination
The Cambridge Structural Database·2023Open Access
Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4
Journal of Medicinal Chemistry·2023· 22 citedOpen Access
Structure-based development of potent Plasmodium falciparum M1 and M17 aminopeptidase selective and dual inhibitors via S1′-region optimisation
European Journal of Medicinal Chemistry·2022· 7 cited
RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting
Frontiers in Cellular and Infection Microbiology·2022· 20 citedOpen Access
The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria
ACS Medicinal Chemistry Letters·2022· 20 citedOpen Access
Basis for drug selectivity of plasmepsin IX and X inhibition in Plasmodium falciparum and vivax
Structure·2022· 27 cited
Insights Into Drug Repurposing, as Well as Specificity and Compound Properties of Piperidine-Based SARS-CoV-2 PLpro Inhibitors
Frontiers in Chemistry·2022· 46 citedOpen Access
The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL
Cell Death and Disease·2022· 19 citedOpen Access
Basis for drug selectivity of plasmepsin IX and X inhibition for Plasmodium falciparum and vivax
2021· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Brad E. Sleebs(20), Guillaume Lessène(17), Alan F. Cowman(16), Peter E. Czabotar(15), Anna Ngo(12), David C.S. Huang(11), Richard W. Birkinshaw(9), Paola Favuzza(9), Bernadine G.C. Lu(8), David Komander(8), Anthony N. Hodder(8), Justin A. Boddey(8), Dale J. Calleja(7), Nathan W. Kuchel(7), Amanda E. Au(7), Jeffrey P. Mitchell(7), Brian J. Smith(7), Theresa Klemm(6), Mark F. van Delft(6), Hélène Jousset Sabroux(6)